Market Overview

Cyclacel Reports Positive Phase 2 Data of Sapacitabine for MDS at ASH


Cyclacel Pharmaceuticals (Nasdaq: CYCC) (Nasdaq: CYCCP) today announced new, primary endpoint data from an ongoing, open-label, multicenter, randomized Phase 2 trial of oral sapacitabine capsules, the Company's lead product candidate, in older patients with myelodysplastic syndromes (MDS) after treatment failure of front-line hypomethylating agents, such as azacitidine and/or decitabine. The 7-day dose regimen of 200 mg twice daily (Arm G), appears to be a better schedule with a one-year survival rate of 38%, median overall survival of approximately 10 months and response rate of 19%. The 30-day mortality from all causes for all patients is 5%. Data were presented at a poster on December 8, 2013 during the 2013 American Society of Hematology (ASH) Meeting and Exposition held in New Orleans, LA.#ASH13

See full press release

Posted-In: News Guidance Management Global


Related Articles (CYCC + CYCCP)

View Comments and Join the Discussion!